Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · IEX Real-Time Price · USD
20.66
-0.87 (-4.04%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for SNDX stock have an average target of 35.25, with a low estimate of 23 and a high estimate of 45. The average target predicts an increase of 70.62% from the current stock price of 20.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SNDX stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 9 | 9 | 9 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +79.09% | Jun 28, 2024 |
| Stifel | Stifel | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +103.29% | Jun 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +98.45% | Jun 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +98.45% | Jun 6, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $34 | Buy | Maintains | $34 | +64.57% | May 21, 2024 |
Financial Forecast
Revenue This Year
31.57M
Revenue Next Year
109.95M
from 31.57M
Increased by 248.23%
EPS This Year
-3.69
from -2.98
EPS Next Year
-3.02
from -3.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 87.2M | 205.6M | 354.3M | 472.8M | 561.4M |
| Avg | 31.6M | 110.0M | 231.7M | 367.4M | 501.8M |
| Low | 5.9M | 66.7M | 178.7M | 304.3M | 426.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 551.3% | 222.2% | 104.1% | 52.8% |
| Avg | - | 248.2% | 110.7% | 58.6% | 36.6% |
| Low | - | 111.4% | 62.5% | 31.3% | 16.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.21 | -1.12 | -1.03 | -0.65 | 0.26 |
| Avg | -3.69 | -3.02 | -2.01 | -1.10 | -0.26 |
| Low | -3.95 | -3.83 | -2.64 | -1.66 | -0.90 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.